initial public offerings (IPOs) trading on American exchanges

Tuesday, May 19, 2015

InVitae (NVTA) began trading on the NYSE on 12 Feb 2015


Invitae Corporation is a genetic information company. The Company is engaged in genetic diagnostics for hereditary disorders, including breast, colon and pancreatic cancer. The Company utilizes an integrated portfolio of laboratory processes, software tools and informatics capabilities to process deoxyribonucleic acid (DNA)-containing samples, analyze information about patient-specific genetic variation and generate test reports for physicians and their patients. The Company offers the following panels: Featured cancer panels, Featured cardiology panels and Featured neurology panels. The Company’s tools and services include genetic counseling services, to explain complex genetic concepts; Family History Tool, which allows digitally recording the patient’s pedigree, assessing their risks, as well as deciding on the appropriate genetic test, and Clinvitae, a database of clinically-observed genetic variants aggregated from public sources.


458 Brannan St
SAN FRANCISCO, CA 94107-1713
United States

Key stats and ratios

Q4 (Dec '14)2014
Net profit margin-1749.14%-2960.85%
Operating margin-1746.63%-2952.12%
EBITD margin--2807.79%
Return on average assets-60.80%-52.22%
Return on average equity--

No comments:

Post a Comment